Equity Research · June 2026 · Industrial / A&D / Medical Technology
ALNT
Allient Inc.
Precision Motion Control & Electronics · NASDAQ · Small Cap
⭐ STRONG BUY Initiating Coverage
STRONG BUY
Price Target: $85
Current: $79.16 | Implied upside: +7.4%
52W: $30–$80 | Mkt Cap: $1.35B
FY2025 EPS: $1.32 | Fwd P/E: 37.7× | SmartScore: 10
Investment Thesis: Allient Inc. is the best-performing stock in our coverage universe over the past 12 months (+160.4%), and we believe the market is still underpricing the earnings trajectory ahead. The company designs and manufactures precision motion control components, subsystems, and electronics for defense, medical, industrial, and space applications — markets with secular tailwinds and pricing power. Allient's EPS is in a steep recovery phase: from $1.32 (FY2025) to an estimated $2.10 (FY2026E) and $3.00 (FY2027E) — a 127% two-year CAGR. The SmartScore is a perfect 10, the analyst consensus is 4 Strong Buys vs. 1 Hold, and the HF Score of 0.68 confirms institutional accumulation. We set an internal PT of $85 (above the consensus $73.80) based on 40× FY2026E EPS, reflecting the re-rating justified by defense demand acceleration and margin recovery.
⚠️ Valuation Note: Current stock price of $79.16 is above consensus analyst PT of $73.80. Our internal PT of $85 reflects forward EPS of $2.10E (FY2026) at 40× — a premium for the EPS recovery trajectory and defense end-market growth. Small-cap volatility is elevated: expect 15–25% drawdowns during market stress.
Income Statement Forecast
| Metric | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E |
|---|
| Revenue ($M) | $370 | $430 | $500 | $554 | $640 | $740 |
| Rev. Growth | +15.6% | +16.2% | +16.3% | +10.8% | +15.5% | +15.6% |
| Gross Profit ($M) | $101 | $122 | $143 | $161 | $195 | $236 |
| Gross Margin | 27.3% | 28.4% | 28.6% | 29.1% | 30.5% | 31.9% |
| Op. Income ($M) | $24 | $29 | $33 | $40 | $60 | $85 |
| Op. Margin | 6.5% | 6.7% | 6.6% | 7.2% | 9.4% | 11.5% |
| EBITDA ($M) | $55 | $66 | $70 | $73 | $96 | $130 |
| EBITDA Margin | 14.9% | 15.3% | 14.0% | 13.2% | 15.0% | 17.6% |
| Net Income ($M) | $14.5 | $17.1 | $19.7 | $22.0 | $35.9 | $51.3 |
| EPS (Diluted) | $0.85 | $1.00 | $1.15 | $1.32 | $2.10 | $3.00 |
| FCF ($M) | $28 | $35 | $42 | $49.7 | $68 | $95 |
E = analyst consensus estimates. FY ends December. EPS inflecting sharply from FY2026 on operating leverage and defense mix shift. Revenue CAGR ~15-16% sustained on backlog visibility.
12-Month Price vs. $85 PT
Revenue & EPS Trend (EPS Recovery)
Balance Sheet & Capital Returns
| Metric | FY2022A | FY2023A | FY2024A | FY2025A | FY2026E | FY2027E |
|---|
| Total Assets ($M) | $580 | $640 | $700 | $760 | $820 | $900 |
| Total Debt ($M) | $240 | $260 | $270 | $265 | $230 | $180 |
| Net Debt ($M) | $220 | $235 | $242 | $240 | $198 | $130 |
| Total Equity ($M) | $340 | $380 | $430 | $495 | $550 | $630 |
| Net Debt/EBITDA | 4.0× | 3.6× | 3.5× | 3.3× | 2.1× | 1.0× |
| Dividends Paid ($M) | $5 | $6 | $6 | $7 | $8 | $9 |
| Share Buybacks ($M) | $5 | $8 | $10 | $12 | $18 | $28 |
Valuation Framework — $85 PT
P/E — FY2026E
$85
~40× on $2.10E EPS · Growth premium reflects 127% two-year EPS CAGR and underfollowed small-cap re-rating potential
EV/EBITDA
$82
~17× FY2026E EBITDA $96M · Small cap defense premium; growth premium for margin expansion story
Price/Sales
$88
~2.1× FY2026E revenue $640M · High-growth industrial companies with defense exposure trade 1.8–2.5× sales
Scenario Analysis
🚀 Bull Case
$110
+39% upside
Defense demand accelerates; EBITDA margins hit 20%+; EPS reaches $4.00 FY2027; multiple expands to 45× on growth. Additional analyst coverage triggers institutional buying. Revenue $800M+ by FY2027.
📊 Base Case
$85
+7.4% upside
EPS recovery trajectory on track: $2.10E FY2026, $3.00E FY2027; margins expand to 17.6%; 40× on forward earnings. Stock consolidates and re-rates higher as earnings confirm the growth story.
⚠️ Bear Case
$45
-43% downside
Program delays; margin recovery stalls; EPS disappoints at $1.50–1.80; net debt concerns re-emerge; multiple compresses to 25×. Small-cap liquidity risk amplifies any sell-off. Stock -43% from current.
Catalyst Timeline
Aug 2026
Q2 2026 Earnings — EPS Inflection
First full quarter showing the FY2026 EPS ramp; revenue growth rate and margin expansion commentary are key
FY2026
Defense Contract Announcements
DoD program wins for unmanned systems, ground vehicles, naval electronics drive backlog visibility
FY2026
New Analyst Initiations
Currently 5 analysts; each new coverage initiation from a mid-tier or major bank re-rates this underfollowed small cap
FY2026-27
Leverage Paydown Milestone
Net Debt/EBITDA declining from 3.3× toward 1.0×; reaching sub-2× is a balance sheet de-risking catalyst
FY2027
$100M+ FCF Milestone
Crossing $100M annual FCF unlocks buyback optionality and changes the capital allocation narrative
Risk Register
HIGH
Small-Cap Volatility
$1.35B market cap = 15–25% swings on earnings misses; limited institutional support on sell-offs
HIGH
Stock Above Consensus PT
At $79 vs. consensus $73.80 — any guidance cut triggers outsized downside vs. larger caps
MED
Leverage Overhang
Net Debt/EBITDA 3.3× is elevated; rate increases or earnings miss could strain covenants
MED
Defense Budget Timing
Program spending tied to congressional appropriations; continuing resolutions delay revenue recognition
LOW
Integration Risk
ALNT grows partly by acquisition; integration execution risk exists but management has strong track record
Market Sentiment
Analyst Rating
Strong Buy
4B / 1H / 0S
Consensus PT
$73.80
Below current price
Internal PT
$85
Our estimate
HF Score
0.68 Buy
Institutional buy
Short Interest
~3.5%
Moderate small cap
Technical (MA)
Buy
RSI 67.6
1Y Return
+160.4%
#1 in coverage
Bottom Line — Strong Buy · PT $85
Allient Inc. has delivered the most spectacular return in our coverage universe over the past 12 months (+160.4%), and the fundamental story is still accelerating. The EPS trough of $1.32 in FY2025 is giving way to a recovery toward $2.10E and $3.00E that the market is only beginning to price in. With a perfect SmartScore 10, 4 of 5 analysts at Strong Buy, HF Score 0.68 confirming institutional accumulation, and margin expansion driven by operating leverage and defense mix shift, ALNT has the hallmarks of a quality compounder in early innings. The stock's primary risk is its small-cap vulnerability: the 3.3× net leverage ratio needs to decline toward 1× by FY2027, and any guidance cut from current elevated expectations would cause a sharp drawdown. However, for investors comfortable with volatility, the 127% two-year EPS CAGR embedded in our model is exceptional. We set our internal PT at $85 — above the consensus $73.80 — based on the EPS recovery and defense demand acceleration. Initiating with Strong Buy. Price Target: $85 (+7.4%). Key catalyst: Q2 2026 earnings with first full demonstration of FY2026 EPS ramp and leverage reduction trajectory.